REG - Hutchmed China Ltd - Grant of Share Options and Awards under LTIP

HUTCHMED (China)Announcement

15/12/2021 09:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211215:nRSO7416Va&default-theme=true

RNS Number : 7416V  Hutchmed (China) Limited  15 December 2021

Grant of Share Options under Share Option Scheme and Awards under Long Term Incentive Plan

 

Hong Kong, Shanghai, & Florham Park, NJ: Wednesday, December 15, 2021:
HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; HKEX: 13) announces
that on December 14, 2021, it granted share options under the Share Option
Scheme adopted by HUTCHMED in 2015 as refreshed in April 2020 (the "Share
Option Scheme") and conditional awards ("LTIP Awards") under the Long Term
Incentive Plan adopted by HUTCHMED in 2015 ("LTIP").

 

Aimed at attracting and retaining top talent, the Remuneration Committee of
HUTCHMED appointed an independent advisor to conduct a compensation
benchmarking research on peer group U.S. and China biotech companies. The
Remuneration Committee comprehensively reviewed the compensation and
share-based incentives policies of HUTCHMED and its subsidiaries (the "Group")
and established an attractive policy to ensure the Group is able to recruit
and retain top talent. Vesting of share-based awards under the policy is in
line with that peer group.

 

HUTCHMED granted share options under its Share Option Scheme to Dr Weiguo Su
(Executive Director and Chief Scientific Officer of the Company) and 14 other
employees to subscribe for a total of 808,940 Ordinary Shares represented by
161,788 American Depositary Shares ("ADSs") (each equating to five Ordinary
Shares) subject to the acceptance of the grantee.

 

Details of such share options granted prescribed are as follows:

 

 Date of grant                                                         :  December 14, 2021

 Exercise price of share options granted                               :  US$35.21 per ADS (equivalent to HK$54.93 per Ordinary Share at the conversion
                                                                          rate HK$7.8=US$1) (such exercise price has been determined by reference to the
                                                                          price of the Ordinary Shares on The Stock Exchange of Hong Kong Limited
                                                                          ("HKEX"))

 Number of share options granted                                       :  808,940 represented by 161,788 ADSs (five share options shall entitle the
                                                                          holder thereof to subscribe for one ADS)

 Closing market price of ordinary shares at HKEX on the date of grant  :  US$35.00 per ADS (equivalent to HK$54.60 per Ordinary Share at the conversion

                                                                        rate HK$7.8=US$1)

 Validity period of the share options                                  :  From December 14, 2021 to December 13, 2031

 Vesting period of the share options                                   :  The share options will vest at 25% on each of the first, second, third and
                                                                          fourth anniversaries of the date of grant of share options.

 

Among the share options granted, 24,930 share options represented by 4,986
ADSs were granted to Dr Weiguo Su (Executive Director and Chief Scientific
Officer of the Company), being a person discharging managerial responsibility
under the UK Market Abuse Regulation.

 

At the same time, HUTCHMED also granted two employees of the Group with
non-performance based LTIP Awards.

 

The notification set out below is provided in accordance with the requirements
of the UK Market Abuse Regulation.

 

Dr Weiguo Su

 

 1    Details of the person discharging managerial responsibilities/person closely
      associated

 a)   Name                                                          Dr Weiguo Su

 2    Reason for the notification

 a)   Position/status                                               Executive Director and Chief Scientific Officer

 b)   Initial notification/Amendment                                Initial notification

 3    Details of the issuer, emission allowance market participant, auction
      platform, auctioneer or auction monitor

 a)   Name                                                          HUTCHMED (China) Limited

 b)   LEI                                                           2138006X34YDQ6OBYE79

 4    Details of the transaction(s): section to be repeated for (i) each type of
      instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument   Option over American Depositary Share (each equating to five Ordinary Shares

                                                             of US$0.10)

      Identification code

                                                                    Option over American Depositary Share with ADS ISIN: US44842L1035

 b)   Nature of the transaction                                     Grant of options in respect of 24,930 Ordinary Shares represented by 4,986

                                                             ADSs under the Share Option Scheme.

                                                             The share options granted are exercisable subject to a vesting schedule of 25%
                                                                    on each of the first, second, third and fourth anniversaries of the effective
                                                                    date of grant.

Price(s)  Volume(s)
 c)   Price(s) and volume(s)                                        Nil       4,986

 d)   Aggregated information                                        N/A

      - Aggregated volume
      - Price

 e)   Date of the transaction                                       2021-12-14

 f)   Place of the transaction                                      Outside a trading venue

 

d)

 

Aggregated information

 -  Aggregated volume
 -  Price

 

N/A

 

e)

 

Date of the transaction

 

2021-12-14

 

 

f)

 

Place of the transaction

 

Outside a trading venue

 

 

 

About HUTCHMED

 

HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is an innovative, commercial-stage,
biopharmaceutical company. It is committed to the discovery, global
development and commercialization of targeted therapies and immunotherapies
for the treatment of cancer and immunological diseases. It has more than 4,500
personnel across all its companies, at the center of which is a team of over
1,400 in oncology/immunology.  Since inception it has advanced eleven cancer
drug candidates from in-house discovery into clinical studies around the
world, with its first three oncology drugs now approved and marketed in China.
For more information, please visit: www.hutch-med.com or follow us on
LinkedIn.

 

 

Forward-Looking Statements

 

This announcement contains forward-looking statements within the meaning of
the "safe harbor" provisions of the U.S. Private Securities Litigation Reform
Act of 1995. Forward-looking statements involve risks and uncertainties.
Existing and prospective investors are cautioned not to place undue reliance
on these forward-looking statements, which speak only as of the date hereof.
For further discussion of these and other risks, see HUTCHMED's filings with
the U.S. Securities and Exchange Commission, on AIM and on HKEX. HUTCHMED
undertakes no obligation to update or revise the information contained in this
announcement, whether as a result of new information, future events or
circumstances or otherwise.

 

 

CONTACTS

 

 Investor Enquiries
 Mark Lee, Senior Vice President    +852 2121 8200
 Annie Cheng, Vice President        +1 (973) 567 3786

 Media Enquiries
 Americas - Brad Miles,             +1 (917) 570 7340 (Mobile)

                                  bmiles@troutgroup.com (mailto:bmiles@troutgroup.com)
 Solebury Trout
 Europe - Ben Atwell / Alex Shaw,   +44 20 3727 1030 / +44 7771 913 902 (Mobile) /

                                  +44 7779 545 055 (Mobile)
 FTI Consulting                     HUTCHMED@fticonsulting.com
                                    (file:///C:/Users/ncharles/AppData/Local/Microsoft/Windows/INetCache/Content.Outlook/2CF922J0/HUTCHMED@fticonsulting.com)
 Asia - Zhou Yi,                    +852 9783 6894 (Mobile)

 Brunswick                          HUTCHMED@brunswickgroup.com
                                    (file:///C:/Users/ncharles/AppData/Local/Microsoft/Windows/INetCache/Content.Outlook/2CF922J0/HUTCHMED@brunswickgroup.com)

 Nominated Advisor
 Atholl Tweedie / Freddy Crossley,  +44 (20) 7886 2500

 Panmure Gordon (UK) Limited

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHFFDSUIEFSEDE